



Ovarian Cancer: Clinical Advances and Challenges

Guest Editors:

Dr. Carmine Conte

Department of General Surgery
and Medical Surgical Specialties,
Gynecological Clinic, University
of Catania, 95123 Catania, Italy

Dr. Luigi Della Corte

Gynecology and Obstetrics Unit,
Department of Neuroscience,
Reproductive Sciences and
Dentistry, School of Medicine,
University of Naples Federico II,
Naples, Italy

Deadline for manuscript
submissions:

closed (25 November 2023)

Message from the Guest Editors

Dear Colleagues,

Ovarian cancer (OC) is the most lethal gynecological malignancy. Early-stage detection and diagnostic tools for OC screening are not efficient. To date, almost 75% of patients are diagnosed at an advanced stage of disease, with a five-year overall survival of about 30%.

Recently, a consequence of the knowledge of different molecular pathways influencing OC is that personalized surgery and target therapies are now a realness. Neoadjuvant chemotherapy before interval debulking surgery (IDS) and adjuvant treatment are considered a valid alternative to PDS in selected patients.

There is an increasing interest in using anti-angiogenic drugs, PARP-inhibitors (PARPi), and immunomodulation. Moreover, minimally invasive surgical (MIS) techniques have been increasingly used in ovarian cancer, considering they provide several benefits compared to the open approach. The MIS approach is under investigation in selected cases of early-stage OC, IDS, and recurrent disease.

Our purpose is to report the most recent knowledge on the management of ovarian cancer, with a look at the different surgical approaches and new therapies to investigate a more accurate, individualized approach.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67081 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, The
University of Tokyo, Tokyo, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)